Xuemei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xuemei Zhang has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Zhi Zhang
Department of Oncology, Tangshan Gongren Hospital
29 shared publicationsHongjiao Wu
College of Life Science, North China University of Science and Technology, Tangshan, Hebei, 063210, China; Department of Oncology Radiation Physics Technology Section, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, 063000, China
23 shared publicationsAng Li
School of Public Health, North China University of Science and Technology
17 shared publicationsYuning Xie
North China Univ Sci & Technol, Sch Publ Hlth, Tangshan 063210, Peoples R China
14 shared publications- Zhi Zhang
Affiliated Tangshan Gongren Hospital, North China University of Science and Technology, Tangshan, China
12 shared publications Zhenbang Yang
School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei, 063210, China
11 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 2002339
Immunotherapy plus chemotherapy versus immunotherapy alone in esophageal cancer: a real-world pharmacovigilance analysis of safety signals and fatal outcomes
Background: Immune checkpoint inhibitors (ICIs) have become an important component of systemic therapy for esophageal cancer, but real-world safety data for combining ICIs with taxane- and platinum-based chemotherapy remain limited. This study compared adverse-event (AE) profiles, time to onset (TTO), and reported mortality between ICI-based combination therapy and ICI monotherapy in esophageal cancer. Methods: Using the FDA adverse event reporting system (FAERS), we screened reports from Q3/2019 through Q1/2026 for esophageal cancer involving pembrolizumab or nivolumab as the primary suspect. Combination included immunotherapy with a taxane and platinum; monotherapy included immunotherapy alone. Disproportionality was assessed via reporting odds ratios ( RORs ) and proportional reporting ratios ( PRRs ). TTO was evaluated using Kaplan-Meier and Cox models , and logistic regression examined factors for reported mortality. Results: Among 1,580 eligible reports (103 combination, 1,477 monotherapy), distinct AE signal profiles emerged. In combination, prominent signals were gastrointestinal, hematologic, and respiratory, with esophagitis showing the strongest signal ( ROR , 61.97; 95%CI , 22.80–168.48), followed by decreased lymphocyte count ( ROR , 59.68; 95%CI , 28.99–122.83) and behaviour disorder ( ROR , 42.85; 95%CI , 13.58–135.17). In monotherapy, signals were more immune-mediated, including immune-mediated cystitis ( ROR , 261.05; 95%CI , 113.92–598.18), immune-mediated cholangitis ( ROR , 87.65; 95%CI , 41.36–185.78), immune-mediated endocrinopathy ( ROR , 85.51; 95%CI , 27.19–268.89) and so on. Among 571 reports with TTO data, AEs occurred significantly earlier in combination than monotherapy, with median TTOs of 23 days ( IQR , 8-72) vs. 49 days ( IQR , 21–129) ( log-rank P < 0.001), consistent across age, sex, weight, and reporting-year subgroups. Reported mortality was 6.8% for combination vs. 21.1% for monotherapy. After multivariable adjustment, combination was associated with lower reported mortality odds than monotherapy ( adjusted OR , 0.27; 95%CI , 0.06–0.77; P = 0.033). Conclusion: ICI-based combination therapy showed a distinct AE profile and significantly earlier AE onset than monotherapy, but lower reported mortality odds. These findings underscore the need for early monitoring of hematologic, gastrointestinal, and respiratory toxicities during combination therapy.
- 5 November 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 2002339
Open AccessImmunotherapy plus chemotherapy versus immunotherapy alone in esophageal cancer: a real-world pharmacovigilance analysis of safety signals and fatal outcomes
Background: Immune checkpoint inhibitors (ICIs) have become an important component of systemic therapy for esophageal cancer, but real-world safety data for combining ICIs with taxane- and platinum-based chemotherapy remain limited. This study compared adverse-event (AE) profiles, time to onset (TTO), and reported mortality between ICI-based combination therapy and ICI monotherapy in esophageal cancer. Methods: Using the FDA adverse event reporting system (FAERS), we screened reports from Q3/2019 through Q1/2026 for esophageal cancer involving pembrolizumab or nivolumab as the primary suspect. Combination included immunotherapy with a taxane and platinum; monotherapy included immunotherapy alone. Disproportionality was assessed via reporting odds ratios ( RORs ) and proportional reporting ratios ( PRRs ). TTO was evaluated using Kaplan-Meier and Cox models , and logistic regression examined factors for reported mortality. Results: Among 1,580 eligible reports (103 combination, 1,477 monotherapy), distinct AE signal profiles emerged. In combination, prominent signals were gastrointestinal, hematologic, and respiratory, with esophagitis showing the strongest signal ( ROR , 61.97; 95%CI , 22.80–168.48), followed by decreased lymphocyte count ( ROR , 59.68; 95%CI , 28.99–122.83) and behaviour disorder ( ROR , 42.85; 95%CI , 13.58–135.17). In monotherapy, signals were more immune-mediated, including immune-mediated cystitis ( ROR , 261.05; 95%CI , 113.92–598.18), immune-mediated cholangitis ( ROR , 87.65; 95%CI , 41.36–185.78), immune-mediated endocrinopathy ( ROR , 85.51; 95%CI , 27.19–268.89) and so on. Among 571 reports with TTO data, AEs occurred significantly earlier in combination than monotherapy, with median TTOs of 23 days ( IQR , 8-72) vs. 49 days ( IQR , 21–129) ( log-rank P < 0.001), consistent across age, sex, weight, and reporting-year subgroups. Reported mortality was 6.8% for combination vs. 21.1% for monotherapy. After multivariable adjustment, combination was associated with lower reported mortality odds than monotherapy ( adjusted OR , 0.27; 95%CI , 0.06–0.77; P = 0.033). Conclusion: ICI-based combination therapy showed a distinct AE profile and significantly earlier AE onset than monotherapy, but lower reported mortality odds. These findings underscore the need for early monitoring of hematologic, gastrointestinal, and respiratory toxicities during combination therapy.
- Open Access
Cancer Risk Linked to Ultra-Processed Foods: Epidemiological Findings, Potential Mechanisms, and Research Outlook
Epidemiological research on ultra-processed food (UPF) consumption and cancer has expanded rapidly; however, the evidence is uneven across cancer sites. Associations were relatively consistent for colorectal cancer, modest and partly attenuated after adjustment for breast cancer, and limited, single-cohort, or largely indirect for lung, pancreatic, renal, and prostate cancers. Recent umbrella reviews have rated the certainty of this evidence as low to very low, reflecting heterogeneous exposure classification, residual confounding, and inconsistent findings. This narrative review synthesizes the current epidemiological evidence on UPF consumption and overall and site-specific cancer risk, evaluates the biological plausibility of three mechanism clusters—obesity-driven metabolic and inflammatory pathways, processing-derived contaminants and food-contact chemicals, and food additives and their mixtures—while distinguishing human evidence from experimental models, and critically examines the NOVA classification as an exposure framework, including its application to non-Western diets. Compared with previous reviews, we appraised the evidence site by site, integrated the most recent umbrella and dose–response meta-analyses, and mapped each proposed mechanism to the tier of evidence supporting it. Standardized NOVA-based exposure assessment, repeated dietary measurements, integration of exposure biomarkers into prospective cohorts, and causal inference frameworks that distinguish confounding from mediation are prerequisites for evidence-based, UPF-specific cancer prevention recommendations.
Open AccessCancer Risk Linked to Ultra-Processed Foods: Epidemiological Findings, Potential Mechanisms, and Research Outlook
Epidemiological research on ultra-processed food (UPF) consumption and cancer has expanded rapidly; however, the evidence is uneven across cancer sites. Associations were relatively consistent for colorectal cancer, modest and partly attenuated after adjustment for breast cancer, and limited, single-cohort, or largely indirect for lung, pancreatic, renal, and prostate cancers. Recent umbrella reviews have rated the certainty of this evidence as low to very low, reflecting heterogeneous exposure classification, residual confounding, and inconsistent findings. This narrative review synthesizes the current epidemiological evidence on UPF consumption and overall and site-specific cancer risk, evaluates the biological plausibility of three mechanism clusters—obesity-driven metabolic and inflammatory pathways, processing-derived contaminants and food-contact chemicals, and food additives and their mixtures—while distinguishing human evidence from experimental models, and critically examines the NOVA classification as an exposure framework, including its application to non-Western diets. Compared with previous reviews, we appraised the evidence site by site, integrated the most recent umbrella and dose–response meta-analyses, and mapped each proposed mechanism to the tier of evidence supporting it. Standardized NOVA-based exposure assessment, repeated dietary measurements, integration of exposure biomarkers into prospective cohorts, and causal inference frameworks that distinguish confounding from mediation are prerequisites for evidence-based, UPF-specific cancer prevention recommendations.
- 12 October 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 228, 105647
Tumor-associated immunosenescence: Mechanisms, biomarkers and age-adaptive immunotherapy
- 12 October 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 228, 105647
Tumor-associated immunosenescence: Mechanisms, biomarkers and age-adaptive immunotherapy
- Open Access
- 10 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Multi-target regulation mechanisms of systemic lupus erythematosus, a network pharmacology and molecular docking study on active compounds from Artemisia argyi
Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disease characterized by persistent immune activation and multi-organ damage. In this study, we integrated network pharmacology, molecular docking, and in vitro validation to identify and prioritize the active compounds, targets, and regulatory pathways of Artemisia argyi (AA). We identified nine candidate active compounds of AA and 380 predicted protein targets. Intersecting these with 218 SLE-associated genes yielded 19 overlapping targets, among which IL2, CASP3, ACE, PPARG, HSP90AA1, and ANXA5 exhibited the highest network connectivity. Functional enrichment analyses highlighted key pathways, including leukocyte activation, IL-17 signaling, and Th17 cell differentiation. Molecular docking revealed favorable binding affinities of quercetin and naringenin with several core targets. Among these, peroxisome proliferator-activated receptor gamma (PPARG) was selected for exploratory validation based on its high network centrality, favorable docking profile, characterized by strong binging affinities (<-5.5 kcal/mol) for both quercetin and naringenin. Subsequent bioinformatic screening identified LTF, CD72, IL13, CHI3L1, and TLR9 as putative SLE-associated genes regulated by PPARG. Experimentally, AA water extract (AAW) upregulated the expression of PPARG and these downstream genes in THP-1-derived macrophages, whereas pharmacological inhibition of PPARG significantly attenuated these effects. These findings suggest that AA modulate PPARG-dependent transcriptional signaling in immune cells, presenting a candidate mechanism that warrants further validation in disease-relevant models.
- 10 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessMulti-target regulation mechanisms of systemic lupus erythematosus, a network pharmacology and molecular docking study on active compounds from Artemisia argyi
Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disease characterized by persistent immune activation and multi-organ damage. In this study, we integrated network pharmacology, molecular docking, and in vitro validation to identify and prioritize the active compounds, targets, and regulatory pathways of Artemisia argyi (AA). We identified nine candidate active compounds of AA and 380 predicted protein targets. Intersecting these with 218 SLE-associated genes yielded 19 overlapping targets, among which IL2, CASP3, ACE, PPARG, HSP90AA1, and ANXA5 exhibited the highest network connectivity. Functional enrichment analyses highlighted key pathways, including leukocyte activation, IL-17 signaling, and Th17 cell differentiation. Molecular docking revealed favorable binding affinities of quercetin and naringenin with several core targets. Among these, peroxisome proliferator-activated receptor gamma (PPARG) was selected for exploratory validation based on its high network centrality, favorable docking profile, characterized by strong binging affinities (<-5.5 kcal/mol) for both quercetin and naringenin. Subsequent bioinformatic screening identified LTF, CD72, IL13, CHI3L1, and TLR9 as putative SLE-associated genes regulated by PPARG. Experimentally, AA water extract (AAW) upregulated the expression of PPARG and these downstream genes in THP-1-derived macrophages, whereas pharmacological inhibition of PPARG significantly attenuated these effects. These findings suggest that AA modulate PPARG-dependent transcriptional signaling in immune cells, presenting a candidate mechanism that warrants further validation in disease-relevant models.
- 19 May 2026
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 26 (1)
CXCL2 is associated with IL-6/JAK2/STAT3 signaling and the immune microenvironment in lung squamous cell carcinoma
Lung squamous cell carcinoma is a major subtype of non-small cell lung cancer and remains a clinical challenge because of limited targeted therapeutic options and a high risk of recurrence after surgical resection. Identifying molecular determinants that connect tumor biology, immune regulation, and therapeutic response is essential for advancing precision medicine. In this study, we employed an integrative multi-omics strategy to investigate the biological and clinical relevance of the chemokine CXCL2 in lung squamous cell carcinoma. Transcriptomic data from The Cancer Genome Atlas and the Gene Expression Omnibus (GSE158420), as well as proteomic data from the Clinical Proteomic Tumor Analysis Consortium, were integrated to systematically analyze CXCL2 expression patterns and clinical correlations. Functional assays were performed to evaluate the effects of CXCL2 on tumor cell proliferation, migration, and invasion. Downstream regulatory mechanisms were explored using differential gene expression analysis, pathway enrichment, gene set variation analysis, and protein-level validation. Tumor immune microenvironment features were assessed using computational immune deconvolution methods, and therapeutic implications were examined through immunotherapy response prediction and drug sensitivity analysis. We found that CXCL2 was significantly downregulated in tumor tissues and cell lines and its expression was associated with gender and advanced clinical stage. In vitro functional experiments demonstrated that CXCL2 suppressed malignant phenotypes of LUSC cells, which was linked to modulation of the interleukin-6, Janus kinase 2, and signal transducer and activator of transcription 3 signaling axis. Moreover, CXCL2 expression correlated with immune-inflamed microenvironment characteristics and drug-specific therapeutic sensitivity patterns. Collectively, these findings highlight CXCL2 as a functionally and clinically relevant biomarker revealed through integrative genomics. While these results support its translational potential as a candidate biomarker for clinical risk stratification, immunotherapy response prediction, and personalized treatment guidance in LUSC, further validation in independent cohorts and mechanistic studies are warranted to confirm its clinical utility.
- 19 May 2026
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 26 (1)
CXCL2 is associated with IL-6/JAK2/STAT3 signaling and the immune microenvironment in lung squamous cell carcinoma
Lung squamous cell carcinoma is a major subtype of non-small cell lung cancer and remains a clinical challenge because of limited targeted therapeutic options and a high risk of recurrence after surgical resection. Identifying molecular determinants that connect tumor biology, immune regulation, and therapeutic response is essential for advancing precision medicine. In this study, we employed an integrative multi-omics strategy to investigate the biological and clinical relevance of the chemokine CXCL2 in lung squamous cell carcinoma. Transcriptomic data from The Cancer Genome Atlas and the Gene Expression Omnibus (GSE158420), as well as proteomic data from the Clinical Proteomic Tumor Analysis Consortium, were integrated to systematically analyze CXCL2 expression patterns and clinical correlations. Functional assays were performed to evaluate the effects of CXCL2 on tumor cell proliferation, migration, and invasion. Downstream regulatory mechanisms were explored using differential gene expression analysis, pathway enrichment, gene set variation analysis, and protein-level validation. Tumor immune microenvironment features were assessed using computational immune deconvolution methods, and therapeutic implications were examined through immunotherapy response prediction and drug sensitivity analysis. We found that CXCL2 was significantly downregulated in tumor tissues and cell lines and its expression was associated with gender and advanced clinical stage. In vitro functional experiments demonstrated that CXCL2 suppressed malignant phenotypes of LUSC cells, which was linked to modulation of the interleukin-6, Janus kinase 2, and signal transducer and activator of transcription 3 signaling axis. Moreover, CXCL2 expression correlated with immune-inflamed microenvironment characteristics and drug-specific therapeutic sensitivity patterns. Collectively, these findings highlight CXCL2 as a functionally and clinically relevant biomarker revealed through integrative genomics. While these results support its translational potential as a candidate biomarker for clinical risk stratification, immunotherapy response prediction, and personalized treatment guidance in LUSC, further validation in independent cohorts and mechanistic studies are warranted to confirm its clinical utility.
- Open Access
- 16 March 2026
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 28 (3) , 581-588
WDR74 gene polymorphisms decrease the risk of esophageal cancer in males
Objectives: The WD repeat domain 74 ( WDR74 ) gene is crucial for ribosome biogenesis and has been implicated in various tumors; however, the impact of its genetic variation on Esophageal Cancer (ESCA) remains unclear. This study aims to investigate the association between WDR74 (WD repeat domain 74) rs11231247 polymorphism and the susceptibility to esophageal cancer (ESCA). Methods: We conducted a case-control study comprising 480 newly diagnosed ESCA patients and 480 healthy controls recruited during the same period. Genotyping of WDR74 rs11231247 was performed using chain reaction-restriction fragment length polymorphism (PCR-RFLP). Non-conditional logistic regression models were used to estimate the association between WDR74 polymorphism and the susceptibility to ESCA. Additionally, bioinformatics analyses were performed using the online tools GEPIA, TNMplot, EWAS Data Hub, MethPrimer, and Pancan-meQTL to explore gene expression and methylation patterns. Results: Bioinformatic analysis revealed that WDR74 expression was significantly upregulated in ESCA tissues compared to adjacent normal tissues and varied significantly by pathological stage (pWDR74 rs11231247 polymorphism is associated with ESCA susceptibility. Specifically, the C allele confers a protective effect against ESCA, particularly in males. These findings, supported by bioinformatic evidence, suggest a potential functional role for WDR74 in esophageal carcinogenesis.
- 16 March 2026
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 28 (3) , 581-588
Open AccessWDR74 gene polymorphisms decrease the risk of esophageal cancer in males
Objectives: The WD repeat domain 74 ( WDR74 ) gene is crucial for ribosome biogenesis and has been implicated in various tumors; however, the impact of its genetic variation on Esophageal Cancer (ESCA) remains unclear. This study aims to investigate the association between WDR74 (WD repeat domain 74) rs11231247 polymorphism and the susceptibility to esophageal cancer (ESCA). Methods: We conducted a case-control study comprising 480 newly diagnosed ESCA patients and 480 healthy controls recruited during the same period. Genotyping of WDR74 rs11231247 was performed using chain reaction-restriction fragment length polymorphism (PCR-RFLP). Non-conditional logistic regression models were used to estimate the association between WDR74 polymorphism and the susceptibility to ESCA. Additionally, bioinformatics analyses were performed using the online tools GEPIA, TNMplot, EWAS Data Hub, MethPrimer, and Pancan-meQTL to explore gene expression and methylation patterns. Results: Bioinformatic analysis revealed that WDR74 expression was significantly upregulated in ESCA tissues compared to adjacent normal tissues and varied significantly by pathological stage (pWDR74 rs11231247 polymorphism is associated with ESCA susceptibility. Specifically, the C allele confers a protective effect against ESCA, particularly in males. These findings, supported by bioinformatic evidence, suggest a potential functional role for WDR74 in esophageal carcinogenesis.
- Open Access
- 10 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1711401
Multi-omics analysis identifies TLRscore for prognostic prediction and highlights TLR8 in macrophage-mediated antitumor immunity of lung adenocarcinoma
Background: Toll-like receptors (TLRs) are key mediators of innate and adaptive immunity. Understanding their role in tumor immunity is essential for improving checkpoint blockade therapies. Methods: Using TCGA data from 32 cancers, we assessed TLR expression, prognosis, and epigenetic changes. A TLRscore was constructed with ssGSEA to evaluate associations with immune infiltration, survival, drug sensitivity, and immunotherapy outcomes, validated in lung adenocarcinoma (LUAD) cohorts. TLR8 polymorphism was genotyped by PCR-RFLP, and the rs3761624 variant was functionally analyzed by luciferase assay. Functional assays in LUAD cells and macrophages treated with the TLR8 agonist Motolimod examined proliferation, migration, invasion, phagocytosis, mitochondrial activity, and ROS generation. Results: TLRs showed altered expression, frequent mutations, copy number variations, and methylation regulation in cancer. High TLRscore predicted favorable prognosis, increased immune infiltration, and improved immunotherapy response in LUAD. TLR8 was the most immunologically relevant, strongly linked to macrophage infiltration, PD-L1 expression, and T-cell activity. The rs3761624 SNP suppressed TLR8 transcription via enhanced NR1D1 repression. Motolimod reprogrammed macrophages toward an M1 phenotype, boosting cytokine secretion, phagocytosis, and antitumor activity, while inhibiting LUAD cell growth. Mechanistically, TLR8 activation in macrophages was associated with reduced mitochondrial membrane potential, increased ROS production, and the acquisition of an M1-like, antitumor phenotype with enhanced phagocytosis and cytokine secretion. Conclusion: TLRscore is a novel biomarker for prognosis and immunotherapy response, while TLR8 represents a promising therapeutic target in LUAD, providing mechanistic insight into potential combination strategies.
- 10 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1711401
Open AccessMulti-omics analysis identifies TLRscore for prognostic prediction and highlights TLR8 in macrophage-mediated antitumor immunity of lung adenocarcinoma
Background: Toll-like receptors (TLRs) are key mediators of innate and adaptive immunity. Understanding their role in tumor immunity is essential for improving checkpoint blockade therapies. Methods: Using TCGA data from 32 cancers, we assessed TLR expression, prognosis, and epigenetic changes. A TLRscore was constructed with ssGSEA to evaluate associations with immune infiltration, survival, drug sensitivity, and immunotherapy outcomes, validated in lung adenocarcinoma (LUAD) cohorts. TLR8 polymorphism was genotyped by PCR-RFLP, and the rs3761624 variant was functionally analyzed by luciferase assay. Functional assays in LUAD cells and macrophages treated with the TLR8 agonist Motolimod examined proliferation, migration, invasion, phagocytosis, mitochondrial activity, and ROS generation. Results: TLRs showed altered expression, frequent mutations, copy number variations, and methylation regulation in cancer. High TLRscore predicted favorable prognosis, increased immune infiltration, and improved immunotherapy response in LUAD. TLR8 was the most immunologically relevant, strongly linked to macrophage infiltration, PD-L1 expression, and T-cell activity. The rs3761624 SNP suppressed TLR8 transcription via enhanced NR1D1 repression. Motolimod reprogrammed macrophages toward an M1 phenotype, boosting cytokine secretion, phagocytosis, and antitumor activity, while inhibiting LUAD cell growth. Mechanistically, TLR8 activation in macrophages was associated with reduced mitochondrial membrane potential, increased ROS production, and the acquisition of an M1-like, antitumor phenotype with enhanced phagocytosis and cytokine secretion. Conclusion: TLRscore is a novel biomarker for prognosis and immunotherapy response, while TLR8 represents a promising therapeutic target in LUAD, providing mechanistic insight into potential combination strategies.
- 13 December 2025
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 195 (2) , 597-607
TLR7 modulates glioblastoma progression through PI3K/AKT/mTOR pathway and immune microenvironment remodeling
Background Glioblastoma (GBM) is an aggressive brain tumor, necessitating the identification of new therapeutic targets. Toll-like receptor 7 (TLR7), a key component of innate immunity, influences oncological processes, but its role in GBM is unclear. This study investigates the impact of TLR7 overexpression on GBM and its underlying mechanisms. Methods Glioblastoma cell lines (U87 and U251) were transfected with a pcDNA-TLR7 plasmid to induce overexpression, verified by qRT-PCR. Proliferation was assessed using CCK-8 and colony formation assays. Migration and invasion were evaluated via Transwell and wound healing assays. Activation of the PI3K/AKT/mTOR signaling pathway was analyzed by Western blotting. Macrophage polarization was studied by exposing M0 macrophages to the TLR7 agonist R837, followed by qRT-PCR and cytokine quantification. Results TLR7 was successfully overexpressed in U87 and U251 cells. TLR7 overexpression significantly reduced GBM cell proliferation, colony formation, migration, and invasion. It suppressed the PI3K/AKT/mTOR signaling pathway. In the tumor microenvironment, TLR7 promoted M1 macrophage polarization, increasing M1 markers and pro-inflammatory cytokines while suppressing M2 markers. Conclusion TLR7 suppresses glioblastoma by inhibiting cell progression via the PI3K/AKT/mTOR signaling pathway and promoting an anti-tumoral immune microenvironment. These findings suggest the potential of TLR7 as a promising therapeutic target for GBM.
- 13 December 2025
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 195 (2) , 597-607
TLR7 modulates glioblastoma progression through PI3K/AKT/mTOR pathway and immune microenvironment remodeling
Background Glioblastoma (GBM) is an aggressive brain tumor, necessitating the identification of new therapeutic targets. Toll-like receptor 7 (TLR7), a key component of innate immunity, influences oncological processes, but its role in GBM is unclear. This study investigates the impact of TLR7 overexpression on GBM and its underlying mechanisms. Methods Glioblastoma cell lines (U87 and U251) were transfected with a pcDNA-TLR7 plasmid to induce overexpression, verified by qRT-PCR. Proliferation was assessed using CCK-8 and colony formation assays. Migration and invasion were evaluated via Transwell and wound healing assays. Activation of the PI3K/AKT/mTOR signaling pathway was analyzed by Western blotting. Macrophage polarization was studied by exposing M0 macrophages to the TLR7 agonist R837, followed by qRT-PCR and cytokine quantification. Results TLR7 was successfully overexpressed in U87 and U251 cells. TLR7 overexpression significantly reduced GBM cell proliferation, colony formation, migration, and invasion. It suppressed the PI3K/AKT/mTOR signaling pathway. In the tumor microenvironment, TLR7 promoted M1 macrophage polarization, increasing M1 markers and pro-inflammatory cytokines while suppressing M2 markers. Conclusion TLR7 suppresses glioblastoma by inhibiting cell progression via the PI3K/AKT/mTOR signaling pathway and promoting an anti-tumoral immune microenvironment. These findings suggest the potential of TLR7 as a promising therapeutic target for GBM.
- 1 July 2025
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 44 (7) , 380-388
STING rs7380824 Polymorphism Contributes to the Susceptibility of Colorectal Cancer in Chinese Population
STING, an endoplasmic reticulum-localized protein with multiple transmembrane domains, has been implicated in colorectal cancer (CRC) development. This study investigated the association between STING rs7380824 polymorphism and CRC susceptibility using both bioinformatics analysis and a case-control study. Bioinformatics predictions from SIFT and PolyPhen indicated that the rs7380824 variant, which results in an amino acid substitution from arginine (R) to glutamine (Q) at position 293, is likely to be deleterious, with a SIFT score of 0.000 and a PolyPhen score of 0.999. A total of 870 CRC patients and 870 healthy controls were genotyped using polymerase chain reaction-restriction fragment length polymorphism. Logistic regression analysis demonstrated that individuals carrying the CT and TT genotypes had an increased risk of CRC with OR (95% CI) of 1.564 (1.115-2.192) and 1.551 (1.271-1.893), respectively. Stratified analysis showed that the rs7380824 C > T variant increased CRC risk in all age and gender groups. Furthermore, non-smokers with the CT or TT genotype had a higher CRC risk (OR = 1.661, 95% CI: 1.333-2.071, p < 0.001), while no significant association was observed among smokers (p = 0.238). Similarly, non-drinkers carrying the CT or TT genotype showed an increased CRC risk (OR = 1.746, 95% CI: 1.395-2.185, p < 0.001), whereas no significant difference was detected among drinkers (p = 0.265). This study identifies STING rs7380824 polymorphism as a significant contributor to CRC susceptibility, with bioinformatics predictions and case-control analysis confirming its deleterious impact and the association with increased CRC risk. In addition, these findings underscore the interplay between genetic and environmental factors in CRC development, highlighting STING's potential as a genetic biomarker for CRC risk assessment in the Chinese population.
- 1 July 2025
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 44 (7) , 380-388
STING rs7380824 Polymorphism Contributes to the Susceptibility of Colorectal Cancer in Chinese Population
STING, an endoplasmic reticulum-localized protein with multiple transmembrane domains, has been implicated in colorectal cancer (CRC) development. This study investigated the association between STING rs7380824 polymorphism and CRC susceptibility using both bioinformatics analysis and a case-control study. Bioinformatics predictions from SIFT and PolyPhen indicated that the rs7380824 variant, which results in an amino acid substitution from arginine (R) to glutamine (Q) at position 293, is likely to be deleterious, with a SIFT score of 0.000 and a PolyPhen score of 0.999. A total of 870 CRC patients and 870 healthy controls were genotyped using polymerase chain reaction-restriction fragment length polymorphism. Logistic regression analysis demonstrated that individuals carrying the CT and TT genotypes had an increased risk of CRC with OR (95% CI) of 1.564 (1.115-2.192) and 1.551 (1.271-1.893), respectively. Stratified analysis showed that the rs7380824 C > T variant increased CRC risk in all age and gender groups. Furthermore, non-smokers with the CT or TT genotype had a higher CRC risk (OR = 1.661, 95% CI: 1.333-2.071, p < 0.001), while no significant association was observed among smokers (p = 0.238). Similarly, non-drinkers carrying the CT or TT genotype showed an increased CRC risk (OR = 1.746, 95% CI: 1.395-2.185, p < 0.001), whereas no significant difference was detected among drinkers (p = 0.265). This study identifies STING rs7380824 polymorphism as a significant contributor to CRC susceptibility, with bioinformatics predictions and case-control analysis confirming its deleterious impact and the association with increased CRC risk. In addition, these findings underscore the interplay between genetic and environmental factors in CRC development, highlighting STING's potential as a genetic biomarker for CRC risk assessment in the Chinese population.